Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589616 | 0.84 | AGBL2 (0.56) | AGBL2BACE1HCAR2NOTUMGABRP | |
| SCHEMBL26928475 | 0.82 | AGBL2 (0.50) | AGBL2BACE1SMN1; SMN2SSTR4HDAC3 | |
| SCHEMBL17668865 | 0.82 | AGBL2 (0.50) | AGBL2BACE1HCAR2SPRSMN1; SMN2 | |
| SCHEMBL1395991 | 0.82 | AGBL2 (0.41) | AGBL2PTGS2BACE1HCAR2SPR | |
| SCHEMBL2592299 | 0.79 | AGBL2 (0.47) | AGBL2BACE1SMN1; SMN2SSTR4NPC1 | |
| SCHEMBL6171824 | 0.79 | NOS3 (0.45) | KCNJ1HCAR2SMN1; SMN2SMORAB9A | |
| SCHEMBL18412762 | 0.78 | ALDH1A1 (0.39) | AGBL2PTGS2HCAR2SPRSSTR4 | |
| SCHEMBL22866557 | 0.78 | AGBL2 (0.39) | AGBL2PTGS2HCAR2SPRGRIN1 | |
| SCHEMBL30259690 | 0.78 | AGBL2 (0.39) | AGBL2PTGS2BACE1HCAR2SPR | |
| SCHEMBL29560615 | 0.78 | AGBL2 (0.39) | AGBL2PTGS2HCAR2SPRGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4301468-A1 | FGFR3 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022187443-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-2747769-B1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1811845-A4 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1811845-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | AGBL2 1072/4885PTGS2 1917/4885BACE1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.